Status:
COMPLETED
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
Lead Sponsor:
University Medical Center Mainz
Conditions:
Neurological Autoimmune Diseases
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases. In the subgroup analysis of ...
Detailed Description
Plasma exchange (PE) and immunoadsorption (IA) are first- or second line treatment options in patients with neurological autoimmune disease, including multiple sclerosis, neuromyelitis optica, chronic...
Eligibility Criteria
Inclusion
- autoimmune neurological therapy refractory disease
Exclusion
- Intake of Angiotensin-converting-enzyme inhibitors (ACE inhibitors) because of allergic reactions by using tryptophan adsorber
- contraindication for any anticoagulation
- contraindication for treatment with citrate dextrose anticoagulation
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04687332
Start Date
June 1 2016
End Date
December 1 2019
Last Update
February 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz I. Medizinische Klinik und Poliklinik
Mainz, Rhineland-Palatinate, Germany, 55130